Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05914194
Other study ID # NLS-1031
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date July 15, 2024
Est. completion date July 30, 2025

Study information

Verified date May 2024
Source NLS Pharmaceutics
Contact Jeff Bernier
Phone 617-905-2282
Email amaze@nls-pharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness. Approximately 48 participants will take part in the study across the United States. The study treatment (NLS-2 or placebo) will be administered for 8 weeks. After this treatment period, the participant may have the option to participate in a separate long-term extension study during which all participants will be treated with NLS-2.


Description:

This is a Phase 3, double-blind, placebo-controlled, multicenter, randomized, parallel-group clinical trial. The primary goal of this study is to assess the efficacy and safety of NLS-2 (mazindol extended-release) tablets in treating Narcolepsy Type 1. The trial aims to determine the effects of NLS-2 on the improvement of narcolepsy symptoms, including cataplexy frequency and excessive daytime sleepiness. Participants in this trial will receive either NLS-2 or a placebo for 8 weeks. The treatment assignment will be concealed from both the participant and the investigator throughout the trial (unless there is an urgent medical need). Approximately 48 patients will be enrolled at multiple clinical sites across the United States. Following the completion of the trial, participants may be given the option to enroll in a separate long-term extension trial where all participants will receive NLS-2 treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date July 30, 2025
Est. primary completion date July 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Adults = 18 years of age at the time of signing the informed consent. - Documented primary diagnosis of Narcolepsy Type 1 (NT1) according to the International Classification of Sleep Disorders-Third Edition (ICSD-3) criteria. - Willing and able to safely discontinue all prohibited medications, including medications for the treatment of narcolepsy. - Body Mass Index (BMI) within the range of 18 - 40 kg/m2 (inclusive). Key Exclusion Criteria: - Any other (besides narcolepsy) clinically relevant medical, behavioral, or psychiatric disorder that is associated with excessive daytime sleepiness or cataplexy. - History of myocardial infarction or significant cardiovascular disease, structural cardiac abnormalities, cardiomyopathy, congestive heart failure, cardiac arrhythmias, coronary artery disease, cerebrovascular disease (transient ischemic attack or stroke), or any other significant cardiac problem. - History of long QT Syndrome or Torsades de Pointes, or an immediate family history of sudden cardiac death. - History of pulmonary hypertension and/or valvulopathy. - History of epilepsy, convulsions, or seizures (excluding early childhood febrile seizures). - Significant history of head injury or head trauma. - Recent or active suicidal ideation or behavior - Current, or within the past year, diagnosis of substance abuse or dependence disorder (SUD) including alcohol abuse. - Narrow-angle glaucoma. - Severe renal or hepatic insufficiency. - Occupation that requires variable or nighttime shift work.

Study Design


Intervention

Drug:
NLS-2
Participants will receive NLS-2 tablets orally.
Placebo
Participants will receive NLS-2 matching placebo tablets orally.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
NLS Pharmaceutics

Outcome

Type Measure Description Time frame Safety issue
Primary Number of cataplexy episodes at Week 8 Cataplexy episodes is a clinical outcome measure that assesses the frequency of cataplexy episodes. 8 weeks
Secondary Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI): change from baseline The Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) scale consists of 8 items to evaluate daytime consequences of functioning on a 5-point Likert scale ranging from 1 to 5. The PROMIS-SRI measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. Each question has five response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and total score ranges from 8 to 40. Higher scores indicates greater sleep impairment. 8 weeks
Secondary Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD): change from baseline The Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) consists of a static 8-item questionnaire. Using a recall period of the past 7 days, it assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Each question has 5 response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and a total score ranges from 8 to 40. Lower scores indicate less sleep disturbance. Negative changes in scores indicate improvement. 8 weeks
Secondary Epworth Sleepiness Scale (ESS): change from baseline The Epworth Sleepiness Scale (ESS) is a patient-reported outcome measure that assesses daytime sleepiness. It asks the participant to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep in 8 different situations or activities that are commonly met in daily life. The total ESS score, ranging from 0 to 24, is the sum of 8 item scores, with higher scores indicating greater daytime sleepiness. 8 weeks
Secondary Patient Global Impression of Severity (PGI-S): change from baseline The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that assesses the participant's perception of the severity of their illness. The participant rates their condition on a point scale, from "no symptoms" to "extremely severe." 8 weeks
Secondary Clinician Global Impression of Severity (CGI-S): change from baseline The Clinical Global Impressions of Severity (CGI-S) is a clinician-rated outcome measure that assesses the clinician's impression of the participant's current illness severity. The clinician rates the severity of the participant's condition on a point scale, from "normal, not at all ill" to "among the most extremely ill patients". 8 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05983731 - A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
Suspended NCT04419792 - 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Completed NCT05375890 - Clinical and Neurophysiological Characteristics of Narcolepsy
Not yet recruiting NCT06292598 - Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
Recruiting NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) Phase 2
Not yet recruiting NCT06457945 - Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions N/A
Not yet recruiting NCT06383806 - Decreasing Nightmares in Adults With Narcolepsy N/A
Completed NCT05687903 - A Study of TAK-861 in Participants With Narcolepsy Type 1 Phase 2
Recruiting NCT05967832 - Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy N/A
Completed NCT05709873 - Narcolepsy Nightmare Study N/A
Recruiting NCT04483310 - Meditation-Relaxation (MR Therapy) for Sleep Paralysis. N/A
Completed NCT04445129 - Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
Completed NCT05460052 - Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
Completed NCT05314556 - Group Psychotherapy in Narcolepsy Type 1 N/A
Recruiting NCT05816382 - A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions Phase 2/Phase 3
Recruiting NCT06336057 - Mentalizating in Adults Suffering From Narcolepsy Type 1.
Recruiting NCT06251063 - Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence N/A
Completed NCT06241911 - Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1 N/A